MedTrace Logo

Mapping of Tumor Stem Cells in the Resection Marigin During Extirpation of Highly Malignant Gliomas Using GlioStem

NCT05556486 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-09-27

No results posted yet for this study

Summary

The study investigates the occurance of GlioStem positive tumor stem cells in the rescection marigins of hig grade human gliomas

Conditions

  • Glioma, Malignant

Interventions

DEVICE

GlioStem

GlioStem is an oligothiophene derivative which can penetrate physiological cell membranes and selectively binds to structures inside the GSCs. GlioStem is conveniently administered ex-vivo onto the investigated tissue or cell culture by a pipette. After only a few minutes, the GSCs will emit green light from GlioStem molecules under blue illumination.

Sponsors & Collaborators

  • Celluminova AB

    collaborator UNKNOWN

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Oscar Persson, MD, PhD · Karolinska University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-05
Primary Completion
2025-05-01
Completion
2025-05-01

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05556486 on ClinicalTrials.gov